Primary bone cancers are extremely rare neoplasms, accounting for less than 0.2% of all cancers. Primary bone cancers show wide clinical heterogeneity and, perhaps most importantly, are often curable. With current multimodality treatment, including multi-agent chemotherapy, approximately three quarters of all patients diagnosed with osteosarcoma are cured. Updates for 2007 include changes in recommendations for treating chondrosarcoma, Ewing's sarcoma, and osteosarcoma.
For the most recent version of the guidelines, please visit NCCN.org
Since opening its doors in 1975, Fred Hutchinson Cancer Research Center (www.fhcrc.org) has developed an international reputation for innovative research that yields lifesaving breakthroughs in the prevention, detection, and treatment of cancer, HIV/AIDS, and other devastating illnesses. The Hutchinson Center houses the world's top cancer-prevention research program and also leads major national and international projects dedicated to the discovery of powerful new tests to diagnose cancer at its most curable stages. Through development of bone-marrow transplantation, the Hutchinson Center has raised survival rates for some forms of leukemia from zero to as high as 85%. This Nobel Prize-winning accomplishment is considered one of the great success stories in cancer research. Through the Center's partnership in the Seattle Cancer Care Alliance, patients receive outstanding personalized care from world-renowned specialists, including prevention clinics for individuals at high risk of developing cancer. The Hutchinson Center is one of 39 National Cancer Institute-designated Comprehensive Cancer Centers nationwide.
Lee Hartwell, PhD (second photo on cover), president and director of the Center, received a Nobel Prize in 2001 for research into how and why the cell cycle goes awry, a process that can lead to the uncontrolled growth characteristic of cancer. His insights are being used in laboratories worldwide to develop treatments for cancer and other diseases.